logo
Plus   Neg
Share
Email

Novartis Settles All Foreign Corrupt Practices Act Investigations

Novartis (NVS) said it has resolved all Foreign Corrupt Practices Act investigations into historical conduct by the company and its subsidiaries. To settle the investigations, the company and certain of its current and former subsidiaries will pay $233.9 million to the Department of Justice and $112.8 million to the SEC.

The SEC found that local subsidiaries or affiliates of Novartis or its former subsidiary Alcon Inc. engaged in schemes to make improper payments or to provide benefits to public and private healthcare providers in South Korea, Vietnam, and Greece in exchange for prescribing or using Novartis or Alcon products. As part of the settlement, Novartis has reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea.

The company noted that the resolutions contain no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT